| ObjectiveTo adopt a prospective randomized clinical controlled study to observe influence of fire needling Sihua acupiont to toxic and side reaction of chemotherapy, quality of life and physical condition, Thl/Th2drift in chemotherapy patients with advanced stage none-small cell lung cancer, thereby, find an effective therapeutic method and a pair of effective acupoints lightening toxic and side reaction of chemotherapy and descent of the quality of life and physical condition caused by chemotherapy, to explore the possible mechanisms of fire needling Sihua acupiont reducing toxic and side reaction of chemotherapy and descent of the quality of life and physical condition in chemotherapy patients with lung cancer.Methods60eligible lung cancer patients with chemotherapy were divided into two groups in simple randomized method, the control group with simple chemotherapy and the treatment group with chemotherapy plus fire needle on SiHua.The chemotherapy included the combination chemotherapy with paclitaxel and Cisplatin or Gemcitabine plus Cisplatin, sufficient hydration was given during chemotherapy, and with the conventional medicine for preventing toxic and side reaction of chemotherapy. Repeat this per21days. As for the fire needle on SiHua, patients with sitting position, after local disinfection of the bilateral Keshu and Tanshu points with cotton balls of2.5%iodine tincture and deiodination with cotton balls of75%alcohol, a thin layer of Wanhua oil was applied on SiHua. Light alcohol lamp, hold a needle like holding a writing brush and burn the fire needle below needle body3cm to white, then prick the red-hot fire needle quickly and accurately into acupoints0. lmm by3times, and pull out agility. Then use a cotton ball to press the acupoints for a moment, and apply a thin layer of wanhua oil on the points. Begin fire needing treatment from the first day of chemotherapy, once a day. One week is a course of treatment. At the first day before chemotherapy and the21st day of chemotherapy, anti-cancer drug toxicity assessment classification level, quality of life and Karnofasky score, cytokines of Thl and Th2were separately evaluated as efficacy indicator. All the data were collected into a database and were analyzed by SPSS18.0statistical software.ResultsCompare of the Karnofasky score:Before the treatment, the Karnofasky score of treatment group is79.30±6.78, the Karnofasky score of control group is78.57±6.71; after the treatment, the Karnofasky score of treatment group is72.53±6.56, the Karnofasky score of control group is66.47±7.57. Before the treatment, there were no significant differences in Karnofasky score between the two groups (P>0.05). After the treatment, the Karnofasky score of two groups were decreased (P <0.01), the Karnofasky score of treatment group was higher than the control group (P<0.01)Compare of the quality of life score:Before the treatment, the quality of life score of treatment group is103.47+4.02, the quality of life score of control group is101.70±5.36; after the treatment, the quality of life score of treatment group is98.77±4.55, t the quality of life score of control group is93.37±3.79. Before the treatment, there were no significant differences in the quality of life score between the two groups (P>0.05). After the treatment, the quality of life score of treatment group was decreased (P<0.01), the quality of life score of control group was decreased (P<0.01), the quality of life score of treatment group was higher than the control group (P<0.01)Compare of blood-system impairment (white blood cell, neutrophil granulocyte, blood platelet, hemoglobin) and the gastrointestinal discomforts (degree of disgusting and vomiting) of anti-cancer drug toxicity reaction:Before the treatment, number of white blood cell of treatment group is (6.97±1.05) X109/L, number of white blood cell of control group is (7.26±0.97) X109/L; after the treatment, number of white blood cell of treatment group is (6.04±0.59) X109/L, number of white blood cell of control group is (5.35±0.58)×109/L. Before the treatment, there were no significant differences in number of white blood cell between the two groups (P>0.05). After the treatment, number of white blood cell of two groups were decreased (P<0.01), number of white blood cell of treatment group was higher than the control group (P<0.01) Before the treatment, number of neutrophil granulocyte of treatment group is (5.40±0.63)×109/L, number of neutrophil granulocyte of control group is (5.29±0.83)×109/L; after the treatment, number of neutrophil granulocyte of treatment group is (4.40±0.65)×109/L, number of neutrophil granulocyte of control group is (3.72±0.73)×109/L. Before the treatment, there were no significant differences in number of neutrophil granulocyte between the two groups (P>0.05). After the treatment, number of neutrophil granulocyte of two groups were decreased (P<0.01), number of neutrophil granulocyte of treatment group was higher than the control group (P<0.01). Before the treatment, number of blood platelet of treatment group is (219.56±43.54)×109/L, number of blood platelet of control group is (220.35±41.78)×109/L; after the treatment, number of blood platelet of treatment group is (198.96±39.20)×109L, number of blood platelet of control group is (175.45±31.88)×109/L. Before the treatment, there were no significant differences in number of blood platelet between the two groups (P>0.05) After the treatment, number of blood platelet of two groups were decreased (P<0.01), number of blood platelet of treatment group was higher than the control group (P<0.05). Before the treatment, number of hemoglobin of treatment group is (116.90±11.15)×109/L, number of hemoglobin of control group is (115.23±10.69)×109/L; after the treatment, number of hemoglobin of treatment group is (110.27±10.39)×109/L, number of hemoglobin of control group is (101.19±9.41)×109/L. Before the treatment, there were no significant differences in number of hemoglobin between the two groups (P>0.05). After the treatment, number of hemoglobin of two groups were decreased (P<0.01), number of hemoglobin of treatment group was higher than the control group (P<0.01). After the treatment, there were significant differences in extent of disgusting and vomiting of two groups (P<0.05)Compare of level of cytokines (IL-2、INF-γ、TNF-α) relate to Th1: Before the treatment, level of IL-2of treatment group is (50.26±14.71) pg/ml, level of IL-2of control group is (56.66±15.29) pg/ml; after the treatment, level of IL-2of treatment group is (94.77±23.85) pg/ml level of IL-2of control group is (80.12±14.21) pg/ml. Before the treatment, there were no significant differences in level of IL-2between the two groups (P>0.05). After the treatment, level of IL-2of two groups were increased (P<0.01), level of IL-2of treatment group was higher than the control group (P<0.01). Before the treatment, level of INF-γ of treatment group is (54.42±18.13) pg/ml, level of INF-γ of control group is (52.81±14.19) pg/ml; after the treatment, level of INF-γ of treatment group is (105.57±30.99) pg/ml, level of INF-γ of control group is (84.05±26.37) pg/ml. Before the treatment, there were no significant differences in level of INF-γ between the two groups (P>0.05). After the treatment, level of INF-γ of two groups were increased (P<0.01), level of INF-γ of treatment group was higher than the control group (P<0.01). Before the treatment, level of TNF-α of treatment group is (219.99±31.59) pg/ml, level of TNF-α of control group is (200.97±43.65) pg/ml; after the treatment, level of TNF-α of treatment group is (147.81±32.82) pg/ml, level of TNF-α of control group is (172.61±31.83) pg/ml. Before the treatment, there were no significant differences in level of TNF-α between the two groups (P>0.05). After the treatment, level of TNF-α of treatment group was decreased (P<0.01), level of TNF-α of control group was decreased (P<0.01), level of TNF-a of treatment group was higher than the control group (P<0.01)Compare of level of cytokines (IL-4、IL-6、IL-10) relate to Th2: Before the treatment, level of IL-4of treatment group is (81.71±33.57) pg/ml, level of IL-4of control group is (66.08±30.61) pg/ml; after the treatment, level of IL-4of treatment group is (38.13±11.56) pg/ml, level of IL-4of control group is (53.94±27.16) pg/ml. Before the treatment, there were no significant differences in level of IL-4between the two groups (P>0.05). After the treatment, level of IL-4of treatment group was decreased (P<0.01), there were no significant differences in level of IL-4between before and after treatment of the control groups (P>0.1), level of IL-4of treatment group was lower than the control group (P<0.01). Before the treatment, level of IL-6of treatment group is (208.60±60.36) pg/ml, level of IL-6of control group is (206.51 ±47.35)pg/ml; after the treatment, level of IL-6of treatment group is (131.00±37.30) pg/ml, level of IL-6of control group is (175.48±54.11) pg/ml. Before the treatment, there were no significant differences in level of IL-6between the two groups (P>0.05). After the treatment, level of IL-6of two groups were decreased (P<0.05), level of IL-6of treatment group was lower than the control group (P<0.01) Before the treatment, level of IL-10of treatment group is (8.24±3.21) pg/ml, level of IL-10of control group is (7.47±3.07) pg/ml; after the treatment, level of IL-10of treatment group is (4.71±1.62) pg/ml, level of IL-10of control group is (6.33±2.70) pg/ml. Before the treatment, there were no significant differences in level of IL-10between the two groups (P>0.05). After the treatment, level of IL-10of treatment group was decreased (P<0.01), there were no significant differences in level of IL-10between before and after treatment of the control groups (P>0.05), level of IL-10of treatment group was lower than the control group (P<0.01) ConclusionTo chemotherapy patients with lung cancer, Combined fire needle on SiHua can increase function of Thl cell population and decrease function of Th2cell population to a certain degree, in other words, reverse Thl/Th2drift, enhance immune function of Th1cell, thereby, alleviate toxicity reaction of anti-cancer drug, relieve descending quality of life and physical condition caused by the chemotherapy. |
PDF Full Text Request